CliffBio
small molecule

TIVORBEX

INDOMETHACIN

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyGenus Lifesciences Inc. →View the full company profile on CliffBio

Drug detail

Brand nameTIVORBEX
Active ingredientINDOMETHACIN
Strength20MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
9089471April 2030use U-55
8734847April 2030product
8992982April 2030product

More from Genus Lifesciences Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TIVORBEX patent cliff — loss of exclusivity April 2030 | CliffBio